Gabriel G, Garn H, Wegmann M, Renz H, Herwig A, Kl. The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine. Vaccine. 2007 Dec 10
The most effective countermeasure against a pandemic originating from a highly pathogenic avian influenza virus (HPAIV) is immunoprophylaxis of the human population. We present here a new approach for the development of a pandemic HPAIV live vaccine. Using reverse genetics, we replaced the polybasic hemagglutinin cleavage site of an H7N7 HPAIV with an elastase motif. This mutant was strictly elastase-dependent, grew equally well as the wild-type in cell culture and was attenuated in mice unlike the lethal wild-type. Immunization at 10(6)pfu dosage protected mice against disease and induced sterile immunity; vaccination with homosubtypic or heterosubtypic reassortants led to cross-protection. These observations demonstrate that a mutated hemagglutinin requiring elastase cleavage can serve as an attenuating component of a live vaccine against HPAIV.
See Also:
Latest articles in those days:
- The evolution and transmission dynamics of H3N2 influenza virus identified in a respiratory disease outbreak in companion dogs in Alabama, USA 5 hours ago
- Structural and functional characterization of hemagglutinin E190D and Q226H minor variants in human H5N1 A/British Columbia/PHL-2032/2024 5 hours ago
- Spatial risk factors associated with outbreaks of highly pathogenic avian influenza in Pennsylvania’s commercial poultry farms 5 hours ago
- [preprint]H9N2 avian influenza virus in Bangladesh: three genetically distinct co-circulating subgroups retain a largely conserved antigenic phenotype 6 hours ago
- [preprint]Endogenous serine proteases in MDCK sublines support trypsin-independent influenza A virus replication 6 hours ago
[Go Top] [Close Window]


